Results of a multicenter, controlled, randomized clinical trial evaluating the combination of piperacillin/tazobactam and tigecycline in high-risk hematologic patients with cancer with febrile neutropenia

Journal of Clinical Oncology

Volumn 32, Issue 14, 2014, Pages 1463-1471

  Bucaneve, Giampaolo ^a   Micozzi, Alessandra ^b   Picardi, Marco ^c   Ballanti, Stelvio ^a   Cascavilla, Nicola ^d   Salutari, Prassede ^e   Specchia, Giorgina ^f   Fanci, Rosa ^g   Luppi, Mario ^h   Cudillo, Laura ⁱ   Cantaffa, Renato ^j   Milone, Giuseppe ^k   Bocchia, Monica ^l   Martinelli, Giovanni ^m   Offidani, Massimo ⁿ   Chierichini, Anna ^o   Fabbiano, Francesco ⁿ   Quarta, Giovanni ^p   Primon, Valeria ^q   Martino, Bruno ^r   Manna, Annunziata ^s   Zuffa, Eliana ^t   Ferrari, Antonella ^u   Gentile, Giuseppe ^b   Foà, Robin ^b   Del Favero, Albano ^a   more..

^a SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^e SPIRITO SANTO HOSPITAL   (Italy)

^f UNIVERSITY OF BARI   (Italy)

^g AO Universitaria Careggi   (Italy)

^h UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

ⁱ TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^j Pugliese Ciaccio Regional Hospital   (Italy)

^k UNIVERSITY OF CATANIA   (Italy)

^l UNIVERSITY HOSPITAL OF SIENA   (Italy)

^m EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

ⁿ OSPEDALI RIUNITI   (Italy)

^o SAN GIOVANNI ADDOLORATA HOSPITAL   (Italy)

^p Ospedale A Perrino   (Italy)

^q C Arrigo Children's Hospital   (Italy)

^r BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^s ASL 5   (Italy)

^t SANTA MARIA DELLE CROCI HOSPITAL   (Italy)

^u A O sant'Andrea   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; MINOCYCLINE; PENICILLANIC ACID; PIPERACILLIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; DIARRHEA; FEBRILE NEUTROPENIA; FEMALE; HEMATOLOGIC MALIGNANCY; HIGH RISK PATIENT; HUMAN; INTENTION TO TREAT ANALYSIS; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOMITING; ADOLESCENT; AGED; BACTEREMIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; HEMATOLOGIC DISEASE; MIDDLE AGED; RISK FACTOR; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; BACTEREMIA; CHEMOTHERAPY-INDUCED FEBRILE NEUTROPENIA; DRUG COMBINATIONS; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; MIDDLE AGED; MINOCYCLINE; PENICILLANIC ACID; PIPERACILLIN; RISK FACTORS; YOUNG ADULT;

EID: 84902953885     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.51.6963     Document Type: Article

References (35)

1. Hughes WT, Armstrong D, Bodey GP, et al: From the Infectious Diseases Society of America. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 161:381-396, 1990 (Pubitemid 20107933)
2. Freifeld AG, Bow EJ, Sepkowitz KA, et al: Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 52:56-93, 2011
3. Meunier F, Lukan C: The First European Conference on Infections in Leukaemia-ECIL1: A current perspective. Eur J Cancer 44:2112-2117, 2008
4. Viscoli C, Varnier O, Marchetti M: Infections in patients with febrile neutropenia: Epidemiology, microbiology, and risk stratification. Clin Infect Dis 40:S240-S245, 2005 (Pubitemid 40411205)
5. Wisplinghoff H, Seifert H, Wenzel RP, et al: Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis 36:1103-1110, 2003 (Pubitemid 36553108)
6. Klastersky J, Ameye L, Maertens J, et al: Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agents 30:S51-S59, 2007 (suppl 1)
7. Bucaneve G, Micozzi A, Menichetti F, et al: Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 353:977-987, 2005 (Pubitemid 41262332)
8. Mikulska M, Del Bono V, Raiola AM, et al: Blood stream infections in allogeneic hematopoietic stem cell transplant recipients: Reemergence of Gram-negative rods and increasing antibiotic resistance. Biol Blood Marrow Transplant 15:47-53, 2009
9. Cattaneo C, Quaresmini G, Casari S, et al: Recent changes in bacterial epidemiology and the emergence of fluoroquinolone-resistant Escherichia coli among patients with haematological malignancies: Results of a prospective study on 823 patients at a single institution. J Antimicrob Chemother 61:721-728, 2008 (Pubitemid 351321152)
10. Gudiol C, Calatayud L, Garcia-Vidal C, et al: Bacteraemia due to extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: Clinical features, risk factors, molecular epidemiology and outcome. J Antimicrob Chemother 65:333-341, 2010
11. Trecarichi EM, Tumbarello M, Spanu T, et al: Incidence and clinical impact of extended-spectrum-beta- lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies. J Infect 58:299-307, 2009
12. Del Favero A, Menichetti F, Martino P, et al: A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia. Clin Infect Dis 33:1295-1301, 2001 (Pubitemid 32955177)
13. Cometta A, Calandra T, Gaya H, et al: Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto Infection Program. Antimicrob Agents Chemother 40:1108-1115, 1996
14. Tumbarello M, Sanguinetti M, Montuori E, et al: Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-β- lactamase-producing Enterobacteriaceae: Importance of inadequate initial antimicrobial treatment. Antimicrob Ag Chemother 51:1987-1994, 2007 (Pubitemid 46903084)
15. Schwaber MJ, Carmeli Y: Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: A systematic review and meta-analysis. J Antimicrob Chemother 60:913-920, 2007 (Pubitemid 47617735)
16. Zhanel GG, Karlowsky JA, Rubinstein E, et al: Tigecycline: A novel glycylcycline antibiotic. Expert Rev Anti Infect Ther 4:9-25, 2006
17. Babinchak T, Ellis-Grosse EJ, Dartois N, et al: The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: Analysis of pooled clinical trial data. Clin Infect Dis 41:S354-S367, 2005 (suppl 5)
18. Ellis-Grosse EJ, Babinchak T, Dartois N, et al: The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: Results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 41:S341-S353, 2005 (suppl 5)
19. Gardiner D, Dukart G, Cooper A, et al: Safety and efficacy of intravenous tigecycline in subjects with secondary bacteremia: Pooled results from 8 phase III clinical trials. Clin Infect Dis 50:229-238, 2010
20. Curcio D, Vargas SW, Ugarte Ubiergo S, et al: Tigecycline treatment of critically ill patients: The Latin user experience. Curr Clin Pharmaco 6:18-25, 2011
21. Anthony KB, Fishman NO, Linkin DR, et al: Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline. Clin Infect Dis 46:567-570, 2008 (Pubitemid 351263497)
22. Chemaly RF, Hanmod SS, Jiang Y, et al: Tigecycline use in cancer patients with serious infections: A report on 110 cases from a single institution. Medicine 88:211-220, 2009
23. Gaya H, Klastersky J, Schimpff SC, et al: Protocol for an international prospective trial of initial therapy regimens in neutropenic patients with malignant disease. Eur J Cancer 11:1-4, 1975 (suppl)
24. Clinical and Laboratory Standards Institute. 2007 Performance Standards for Antimicrobial Testing: Seventeenth Informational Supplement. CLSI document M100-S17. Wayne, PA, Clinical and Laboratory Standards Institute, 2007
25. European Committee on Antimicrobial Susceptibility Testing (EUCAST) Steering Committee. EUCAST technical note on tigecycline. Clin Microbiol Infect 12:1147-1149, 2006
26. Falagas ME, Karageorgopoulos DE, Dimopoulos G: Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of tigecycline. Curr Drug Metab 10:13-21, 2009
27. Reinert RR, Low DE, Rossi F, et al: Antimicrobial susceptibility among organisms from the Asia/Pacific Rim Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline. J Antimicrob Chemother 60:1018-1029, 2007 (Pubitemid 47617749)
28. Tasina E, Haidich AB, Kokkali S, et al: Efficacy and safety of tigecycline for the treatment of infectious diseases: A meta-analysis. Lancet Infect Dis 11:834-844, 2011
29. Yahav D, Lador A, Paul M, et al: Efficacy and safety of tigecycline: A systematic review and meta-analysis. J Antimicrob Chemother 66:1963-1971, 2011
30. Prasad P, Sun J, Danner RL, et al: Excess deaths associated with tigecycline after approval based on non-inferiority trials. Clin Infect Dis 54:1699-1709, 2012
31. Gudiol C, Tubau F, Calatayud L, et al: Bacteraemia due to multidrug-resistant Gram-negative bacilli in cancer patients: Risk factors, antibiotic therapy and outcomes. J Antimicrob Chemother 66:657-663, 2011
32. Kang CI, Chung DR, Ko KS, et al: Risk factors for infection and treatment outcome of extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae bacteremia in patients with hematologic malignancy. Ann Hematol 91:115-121, 2012
33. Carmeli Y, Akova M, Cornaglia G, et al: Controlling the spread of carbapenemase-producing Gram-negatives: Therapeutic approach and infection control. Clin Microbiol Infect 16:102-111, 2010
34. ECDC Antimicrobial Resistance and Healthcare-Associated Infections Programme. Antimicrobial resistance 2010: global attention on carbapenemaseproducing bacteria. Euro Sourveil 15:46-49, 2010
35. European Conference on Infection in Leukaemia, Bacterial Resistance in Haematology-ECIL 4. Final version. February 14, 2012. ECIL Web Site: http://www.ebmt.org/Contents/Resources/Library/ECIL/Documents/ ECIL4%202011%20Bacterial%20resistance%20in%20Haematology.pdf